Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$75.92 USD

75.92
3,245,812

+0.42 (0.56%)

Updated Jun 4, 2024 04:00 PM ET

After-Market: $76.14 +0.22 (0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Urmimala Biswas headshot

3 Medical Stocks Poised to Trounce Market on Coronavirus Scare

by Urmimala Biswas

Here are three Medical stocks showing early signs of stellar growth, banking on the choppy global market scenario.

Sreyoshi Mukherjee headshot

Coronavirus to Weigh on These 4 Medical Stocks' Q1 Show

by Sreyoshi Mukherjee

The coronavirus pandemic likely to disrupt the first-quarter performances of players in the MedTech space.

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories

Urmimala Biswas headshot

Coronavirus Ails S&P 500 Index, MedTechs Bear the Brunt

by Urmimala Biswas

S&P 500 MedTech stocks pull the index further down on COVID-19 situation becoming grimmer.

Neovasc (NVCN) Releases Update on Reducer and Tiara Products

by Zacks Equity Research

Neovasc (NVCN) expects an approval from the FDA for Reducer by end of 2020.

Boston Scientific (BSX) Down 12.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sriparna Ghosal headshot

3 MedTech Stocks to Rebound After Coronavirus-Led Recoil

by Sriparna Ghosal

As the coronavirus chaos continues to rise, MedTech firms have been witnessing a spike in demand for protective respiratory equipment.

Aparajita Dutta headshot

Coronavirus Spreads Rapidly Worldwide: Medtech Stocks in Focus

by Aparajita Dutta

The coronavirus outbreak disrupts manufacturing and supply chain in China, which in turn might have taken a toll on U.S. Medtech stocks.

Trina Mukherjee headshot

Medical Products Industry Outlook: Growth Prospects Bright

by Trina Mukherjee

Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.

Trina Mukherjee headshot

3 Medical Product Stocks Likely to Beat This Earnings Season

by Trina Mukherjee

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Sonoco (SON) Meets Q4 Earnings Estimates

by Zacks Equity Research

Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Integer Holdings Stock for Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales. However, intense competition remains a woe.

Boston Scientific (BSX) Q4 Earnings Beat, Margins Decline

by Zacks Equity Research

Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.

Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More

by Zacks Equity Research

Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.

Boston Scientific (BSX) Q4 Earnings Top Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of 4.55% and -0.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

HRC vs. BSX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HRC vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?

by Zacks Equity Research

Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.

Medical Products' Jan 30 Earnings Roster: TMO, EW & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Urmimala Biswas headshot

Medical Products' Earnings Due on Jan 29: ALGN, HOLX & More

by Urmimala Biswas

A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.

Sriparna Ghosal headshot

COPD Devices Gain Regulatory Go-Ahead: 3 Stocks in Focus

by Sriparna Ghosal

Growth in the COPD devices market can be attributed to factors like steadily rising geriatric population, increasing incidence of smoking and chronic respiratory diseases.

What's in Store for Varian Medical (VAR) in Q1 Earnings?

by Zacks Equity Research

Demand for Eclipse and TrueBeam is expected to have driven Varian's (VAR) Oncology revenues in fiscal Q1.

Boston Scientific Gets a Boost From New Products, Buyouts

by Zacks Equity Research

Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Boston Scientific Stock Dips on Dull Preliminary Q4 Results

by Zacks Equity Research

Boston Scientific's (BSX) organic revenue growth will likely lag expectations for both the fourth quarter and 2019.